| Literature DB >> 27617250 |
Ji Hyun Noh1, Tae-Seok Kim1, Keun Soo Ahn1, Yong Hoon Kim1, Koo Jeong Kang1.
Abstract
PURPOSE: This study aimed to determine which factors affect the prognosis of hepatectomy for hepatocellular carcinoma (HCC) larger than 5 cm, including the prognostic difference between tumor sizes from 5-10 cm and larger than 10 cm.Entities:
Keywords: Hepatectomy; Hepatocellular carcinoma; Prognosis
Year: 2016 PMID: 27617250 PMCID: PMC5016599 DOI: 10.4174/astr.2016.91.3.104
Source DB: PubMed Journal: Ann Surg Treat Res ISSN: 2288-6575 Impact factor: 1.859
Clinical features of 114 patients who underwent resection for single hepatocellular carcinoma larger than 5 cm
Values are presented as mean ± standard deviation, number (%), or median (range).
ICG R-15, Indocyanine green retention at 15 minutes; PIVKA-II, prothrombin induced by vitamin K absence or antagonist-II.
Pathologic features of 114 patients who underwent resection for single hepatocellular carcinoma larger than 5 cm
Comparison of clinicopathologic features of patients underwent resection for single hepatocellular carcinoma larger than 5 cm
Values are presented as mean±standard deviation or number (%).
PIVKA-II, prothrombin induced by vitamin K absence or antagonist-II; ICG R-15, Indocyanine green retention at 15 minutes.
Fig. 1Overall survival curve (A) and recurrence-free survival curve (B) according to tumor size, between 5–10 cm and over 10 cm.
Fig. 2Overall survival curve (A) and recurrence-free survival curve (B) for entire cohort after surgical resection for single hepatocellular carcinoma larger than 5 cm. The 1-, 3-, and 5-year overall survival rates were 79%, 57%, and 50%. The 1-, 3-, and 5-year recurrence-free survival rates were 53%, 36%, and 29%, respectively.
Prognostic factors associated with hepatocellular carcinoma recurrence
HR, hazard ratio; CI, confidence interval; PIVKA-II, prothrombin induced by vitamin K absence or antagonist-II.
Fig. 3Recurrence-free survival curves according to HBV (A), prothrombin induced by vitamin K absence or antagonist-II (B), the presence of portal vein gross invasion (C), and the presence of microvascular invasion (D).